RxDoctor Payments Data

David Duralia, MD

Family Medicine · Hickory, NCNPI 1972549301

Payments from drug & device makers

$11,292in general payments, 2019–2025

Across 742 payments — averaging $15.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • Pfizer$854
  • Lilly USA, LLC$782
  • AstraZeneca$753
  • Johnson & Johnson$398
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$11,270100%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)149$1,757
Novo Nordisk119$1,635
Pfizer56$854
Lilly USA, LLC47$782
AstraZeneca(2 entities)44$753
Johnson & Johnson26$398
Sanofi-aventis U.S. LLC24$390
GSK18$346
Boehringer Ingelheim18$310
Dexcom, Inc.12$286
Bayer14$253
Amgen(2 entities)15$246
Amneal Pharmaceuticals LLC13$238
Takeda Pharmaceuticals U.S.A., Inc.17$216
Merck13$190
Novartis10$164
Supernus Pharmaceuticals, Inc.8$160
Astellas Pharma US Inc10$158
Abbott7$146
Kowa Pharmaceuticals America, Inc.10$145
Amarin Pharma, Inc.8$136
Axsome Therapeutics, Inc.5$105
Sanofi Pasteur Inc.5$95
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC7$94
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$87
Neos Therapeutics, LP6$84
Phathom Pharmaceuticals, Inc.4$80
Exact Sciences5$73
Idorsia Pharmaceuticals US Inc3$64
Tris Pharma Inc4$57
Organon5$57
IBSA Pharma Inc.3$54
Corcept Therapeutics3$53
Teva Pharmaceuticals USA, Inc.4$50
Eisai Inc.3$48
Biohaven Pharmaceutical Holding Company Ltd.3$46
Biohaven Pharmaceuticals, Inc.3$42
Nestle Healthcare Nutrition Inc.3$41
Si-bone, Inc.2$39
Genentech USA, Inc.3$39
Seqirus USA Inc2$38
Vanda Pharmaceuticals Inc.2$38
Renalytix AI, Inc.2$36
Xeris Pharmaceuticals, Inc.2$35
Shire North American Group Inc2$32
Almatica Pharma LLC2$31
Insulet Corporation1$29
Lundbeck LLC1$26
Abiomed1$26
Inari Medical, Inc.1$25
Corium, LLC1$23
Otsuka America Pharmaceutical, Inc.1$23
Boston Scientific1$19
Inspire Medical Systems, Inc.1$19
Evoke Pharma, Inc.1$18
Insmed, Inc.1$16
Adlon Therapeutics L.p.1$14
Therapeuticsmd, Inc.1$13
Dermira, Inc.1$13
Medtronic1$12

How this compares

$11,292 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$237,512
Medicare patients
493
Services billed
4,768

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban160$136,448
OzempicSemaglutide80$73,630
JanuviaSitagliptin Phosphate66$61,077
MyrbetriqMirabegron78$51,570
RybelsusSemaglutide33$41,911
XareltoRivaroxaban46$40,307
Tresiba Flextouch U-100Insulin Degludec59$35,382
JardianceEmpagliflozin40$35,151
Xtampza ErOxycodone Myristate30$34,826
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog35$33,208
MounjaroTirzepatide31$32,137
Xultophy 100-3.6Insulin Degludec/Liraglutide13$31,759
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$28,663
FarxigaDapagliflozin Propanediol47$26,982
Repatha SureclickEvolocumab21$26,415

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6$1,635$147,301126 claims
PfizerEliquis$854$136,448160 claims
MerckJanuvia$190$61,07766 claims
Johnson & JohnsonXarelto, Invokana$398$52,38960 claims
Astellas Pharma US IncMyrbetriq$158$51,57078 claims
Boehringer IngelheimJardiance, Spiriva Respimat$310$46,99555 claims
Lilly USA, LLCMounjaro, Trulicity$782$44,64142 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$753$39,47474 claims
GSKTrelegy Ellipta, Shingrix$346$39,25371 claims
AbbVieVraylar, Synthroid$1,757$26,976164 claims
Amneal Pharmaceuticals LLCUnithroid$238$3,36047 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Hickory

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →